Use of a Mobile Intermittent Pneumatic Compression Device (Vekroosan) in Mobile Patients With Chronic Venous Disease

Abstract

Background: Compression therapy is an essential part of chronic venous disorder (CVD) treatment in reducing associated complications. This observational study aimed to note the use, effects and tolerance of a mobile intermittent pneumatic calf compression (IPC) device, Vekroosan (DVT Solution P/L).

Methods: In 56 patients, Doppler ultrasonography was used to measure venous blood peak flow velocity (PFV) at external iliac, common femoral, distal superficial femoral and popliteal vein levels both before and after application of Vekroosan calf compressor for comparison.

Results: Vekroosan was able to show significant clinical benefit in 45 patients (80%). There was a significant increase in femoral PFV pressure in post-compression measurement when compared to the pre-compression measurement (43.1 vs. 32.4 cm/s, P < 0.001), even when patients mobilize. On average, the PFV pressure increased by 10.7 cm/s when compared to baseline. A significant decrease was seen in calf swelling after calf compression (31.3 vs. 21.9 cm, P < 0.01), also with mobilization. Eighty-seven percent of patients tolerated the device well.

Conclusions: Our study shows that use of mobile IPC devices, such as Vekroosan, is safe and effective in the treatment of CVD, can be used while mobilizing and can achieve results comparable to non-mobile devices.

J Hematol. 2021;10(1):8-13
doi: https://doi.org/10.14740/jh684